EOSE
Eos Energy Enterprises, Inc.
There isn't enough reported data to score EOSE yet.
RXO
RXO, Inc.
RXO lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve, though they disagree widely on how much.
EOSE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
EOSE's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
RXO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Weak |
RXO's revenue is currently healthy, but its profitability, cash flow and balance sheet are under pressure.
EOSE PE Valuation
EOSE has no meaningful PE right now: it lost money over the past year.
RXO PE Valuation
RXO has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 54x next year's earnings.
EOSE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect EOSE's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
RXO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect RXO to return to profit, with revenue growing. However, they disagree widely on these estimates.
EOSE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2023 | -$2.69 | +$0.85 |
| Q2 2023 | -$3.76 | -$1.00 |
| Q1 2023 | -$3.65 | -$0.86 |
| Q4 2022 | -$3.68 | -$1.32 |
| Q3 2022 | -$3.54 | +$5.19 |
RXO has the stronger earnings trend. Trailing diluted EPS is down 224% for EOSE versus RXO down 208%.
RXO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.52 | — |
| Q3 2026 | -$0.52 | -$0.04 |
| Q2 2026 | -$0.62 | +$1.59 |
| Q1 2026 | -$0.62 | +$1.60 |
| Q4 2025 | -$0.59 | +$1.58 |
| Q3 2025 | -$0.48 | +$1.51 |
| Q2 2025 | -$2.21 | -$2.02 |
| Q1 2025 | -$2.22 | -$2.12 |
| Q4 2024 | -$2.17 | -7333% |
RXO is still losing money, but far less than before: $0.52 per share over the past year, against $2.22 at its worst in early 2025.
EOSE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $82.7M | +171% |
| Q2 2026 | $68.8M | +351% |
| Q1 2026 | $57M | +445% |
| Q4 2025 | $58M | +700% |
| Q3 2025 | $30.5M | +3473% |
| Q2 2025 | $15.2M | +1597% |
| Q1 2025 | $10.5M | +58% |
| Q4 2024 | $7.3M | +9.7% |
EOSE has the edge over RXO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -96% | +105 points |
| Q2 2026 | -122% | +297 points |
| Q1 2026 | -139% | +367 points |
| Q4 2025 | -140% | +573 points |
| Q3 2025 | -201% | +6044 points |
| Q2 2025 | -419% | +2815 points |
| Q1 2025 | -506% | +117 points |
| Q4 2024 | -713% | -74 points |
EOSE's operating margin was −96% last quarter, up 105 points from the same quarter a year ago, near the top of its range since 2019.
RXO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.9B | +32% |
| Q2 2026 | $1.8B | +25% |
| Q1 2026 | $1.4B | -0.6% |
| Q4 2025 | $1.5B | -12% |
| Q3 2025 | $1.4B | +37% |
| Q2 2025 | $1.4B | +53% |
| Q1 2025 | $1.4B | +57% |
| Q4 2024 | $1.7B | +70% |
RXO's revenue is growing: $1.9B last quarter, up 32% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 0.9% | +1.4 points |
| Q2 2026 | 0.1% | +0.1 points |
| Q1 2026 | -2% | +0.1 points |
| Q4 2025 | -2.9% | -1.4 points |
| Q3 2025 | -0.5% | +1.4 points |
| Q2 2025 | 0% | 0 points |
| Q1 2025 | -2.1% | -0.8 points |
| Q4 2024 | -1.4% | -2.9 points |
RXO has the edge over EOSE on profitability, with a higher operating margin.
EOSE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$105.1M | -$22.4M |
| Q2 2026 | -$107.4M | -$34.3M |
| Q1 2026 | -$154.8M | -$121M |
| Q4 2025 | -$75.2M | -$19.5M |
| Q3 2025 | -$82.7M | -$28.5M |
| Q2 2025 | -$73.2M | -$40.6M |
| Q1 2025 | -$33.8M | +$10.7M |
| Q4 2024 | -$55.8M | -$10.2M |
EOSE has burned cash in almost every quarter: −$443M over the past year, against −$246M the year before.
RXO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $12M | +33% |
| Q2 2026 | -$52M | -678% |
| Q1 2026 | -$24M | -$7M |
| Q4 2025 | -$9M | +$10M |
| Q3 2025 | $9M | +$27M |
| Q2 2025 | $9M | +$25M |
| Q1 2025 | -$17M | -$13M |
| Q4 2024 | -$19M | -2000% |
RXO has the edge over EOSE on cash flow, with more consistent year-over-year improvement.
EOSE Net Leverage
EOSE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
RXO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 8.4x | High |
| Q2 2026 | 16.0x | High |
| Q1 2026 | 12.9x | High |
| Q4 2025 | 10.5x | High |
| Q3 2025 | 6.3x | High |
| Q2 2025 | 9.2x | High |
| Q1 2025 | 13.4x | High |
| Q4 2024 | 10.7x | High |
RXO's net debt is about 8.4 years of its operating earnings (EBITDA), up from 6.3 years a year ago.
EOSE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.5 | Neutral |
| Stochastic | 7.4 | Oversold |
EOSE's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
RXO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 60.7 | Neutral |
| Stochastic | 85.5 | Overbought |
RXO's weekly RSI is 61 (neutral) and its Stochastic is 85 (overbought).
EOSE PE vs Industrials Sector
EOSE has no meaningful PE right now: it lost money over the past year.
RXO PE vs Industrials Sector
| Metric | RXO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 24x | — |
RXO has no meaningful PE right now: it lost money over the past year.
EOSE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.24 | 19% below |
| 20 week MA | $3.28 | 45% below |
| 50 week MA | $7.01 | 74% below |
| 100 week MA | $7.10 | 75% below |
| 200 week MA | $4.53 | 60% below |
EOSE is in a downtrend: it's below all five of its weekly moving averages, and 60% below its 200-week average.
RXO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $26.6 | 6.3% above |
| 20 week MA | $24.6 | 15% above |
| 50 week MA | $20.4 | 38% above |
| 100 week MA | $18.9 | 49% above |
| 200 week MA | $20.6 | 37% above |
RXO has the edge over EOSE on trend strength, trading above more of its moving averages.
EOSE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.72 | $19.2 | +98% |
| 2021 | $19.2 | $8.57 | -55% |
| 2022 | $8.57 | $1.08 | -87% |
| 2023 | $1.08 | $1.09 | +0.9% |
| 2024 | $1.09 | $5.17 | +374% |
| 2025 | $5.17 | $11.9 | +129% |
| 2026 YTD | $11.9 | $1.81 | -85% |
EOSE's yearly returns have swung widely, from +374% in 2024 to −87% in 2022. It's down 85% so far in 2026.
RXO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $21.5 | $16.3 | -24% |
| 2023 | $16.3 | $23.3 | +43% |
| 2024 | $23.3 | $24.4 | +4.7% |
| 2025 | $24.4 | $12.7 | -48% |
| 2026 YTD | $12.7 | $28.3 | +123% |
RXO has the edge over EOSE on returns for 2026, with the stronger performance.